List view / Grid view
The scientists discovered that dual knockout of genes in organoids grown from human tissue can generate a model of a potential therapeutic target for gastroesophageal junction cancer.
As COVID-19 continues to evolve, researchers are still on the lookout for new ways to protect against the virus. Drug Target Review brings you some of the most recent pre-clinical developments.
The scientists hope the human body plan will increase the understanding of the aetiology and pathology of disease.
Researchers have genetically profiled nearly 200,000 cells from lungs, mapping their precise locations in tissue to discover an unexpected new immune niche in our airways.
Need some direction in choosing immune cell markers? Whether you are working with human cells or a mouse model, CST has you covered!
This exclusive interview highlights some of Dr Arthur Suckow’s insights into how his team uses RNA therapies to treat rare diseases such as Charcot-Marie-Tooth 1A.
Join Malvern Panalytical for a 15-minute webinar to learn about ex vivo inflammasome slice assays for neuroinflammation discovery.
Drug Target Review’s Ria Kakkad recently spoke with Dr Jane Osbourn about her experience as a woman in STEM.
Dr Douglas Ross-Thriepland and Dr David Walter, from the Functional Genomics Centre (FGC) – a joint venture between Cancer Research UK’s (CRUK) drug discovery engine, Cancer Research Horizons, and AstraZeneca – speak to Drug Target Review about their work. The centre’s focus is on genetic screening; cancer models; CRISPR reagent…
Scottish researchers uncovered that drugs used to treat angina and high blood pressure, could be used to treat AKI.
Researchers have presented comprehensive multi-omic profiles to identify genes, non-coding RNAs, proteins, and plasma metabolites involved in NAFLD-to-NASH progression.
Dr Sheraz Gul examines how patient-driven imaging strategies can be utilised to aid the translation of initial research all the way into the clinic.
Despite decades without vaccine development in the respiratory syncytia virus (RSV) space, researchers are now homing in on a potential strategy to protect individuals from this disease. Here, Drug Target Review’s Ria Kakkad spoke with Dr Christy Comeaux, Medical Lead (RSV), Janssen, about the challenges associated with RSV vaccine development and her most promising…
In this article, Drug Target Review’s Izzy Wood and Ria Kakkad share some of the most ground-breaking moments from drug discovery this year.
Japanese researchers proposed using RNA interference for correcting a mistake in the genetic code of patients with Fukuyama Muscular Dystrophy (FCMD).
